<<
>>

Alternative Host Response to MAP Infection

Although later stages of paratuberculosis ap­pear to be associated with a classical Th2-like humoral immune response (Ganusov et al., 2015; Koets et al., 2015), the innate or early re­sponse is not as well understood.

Traditionally, classical Th1 responses are thought to be a major early reaction to MAP infection, via the elevated expression of inflammatory cytokines IFNγ and TNF α (Begg et al., 2011; Dudemaine et al., 2014; Roussey et al., 2014). In later stage infections, a simultaneous decrease of Th1 cy­tokines appears to be coupled to an increase in Th2 cytokines (Roussey et al., 2014; Ganusov et al., 2015; Roussey et al., 2016). Recent work has also highlighted the potential importance of alternative Th17-like responses in early M. tuberculosis and M. bovis infections (Khader et al., 2011; Steinbach et al., 2016). The no­tion that MAP may also be activating this pat­tern of response is supported by macrophage and epithelial cell upregulation of mRNA en­coding the Th17-driving cytokines IL-23, IL-6 and TGFβ (Dudemaine et al., 2014; Everman et al., 2015). Our own research has shown a mean relative percentage increase of CD4, CD8 and γδ T cells expressing the receptor for IL-23 (IL-23R) in peripheral blood mononuclear cells of MAP test-positive cows relative to cells from MAP test-negative cows. This response was in­ducible by MAP in vitro with cells from both MAP test-positive and test-negative cows, sug­gesting that IL-23R upregulation is a general feature of MAP-immune cell interactions. With M. bovis and M. tuberculosis, CD4+ and γδ T cells are the primary producers of the Th17 specific cytokines IL-17a and IL-22 (Steinbach et al., 2016; Basile etal., 2017). Th17 cell activation is a specific and early immune response to M. bovis and M. tuberculosis (Dhiman et al., 2009, 2012; Tzu, 19 71; Waters et al., 2016). Our work has shown that while early lesions from MAP infect­ed tissues express elevated mRNA encoding IL- 17a, tissues exhibiting more advanced infection stages do not (Roussey et al., 2016). Preliminary experimentation with isolated CD3+ T cells from cows also demonstrated a robust innate Th 17 response, with production of enhanced levels of IL-17a following exposure to two strains of MAP or to purified protein derivative of MAP (PPDj). Th17 cells can exhibit a certain plasticity and may also produce IL-10 and IFNγ and be a source of these cytokines during some phases of MAP infection (Zielinski et al., 2012). Finally, the Th17 driving cytokine IL-23 can be highly pro- inflammatory and prolonged expression of IL-23 can limit the effect of regulatory T cells (Ahern etal., 2010; Petermann etal., 2010). To this end, we are exploring the possibility that IL-23 may be one source of the continued inflammation observed in later stages of paratuberculosis.

9.7

<< | >>
Source: Behr Marcel A., Stevenson K., Kapur V. (eds.). Paratuberculosis: Organism, Disease, Control. 2nd edition. — CAB International,2020. — 439 p.. 2020
More medical literature on Medic.Studio

More on the topic Alternative Host Response to MAP Infection:

  1. Innate Response to MAP Infection
  2. Strategic Excellence: MAP Gene Expression Programmes Following Host Cell Entry
  3. Avoid What is Strong, Strike What is Weak: MAP Targets Early Host Responses to Prevent Immune Counterattack
  4. CONCEPT 13.3 Host and parasite populations can evolve together, each in response to selection pressure imposed by the other.
  5. Pathogenesis and Stages of MAP Infection in Cattle
  6. The Effect of Immunosuppressive Therapy on MAP Infection
  7. HOST IMMUNE CELL INFECTION WITH HIV
  8. CONCEPT 13.1 Parasites typically feed on only one or a few host species, but host species have multiple parasite species.
  9. Immune Response
  10. Genomic Epidemiology of MAP
  11. Comparison of the Virulence and Pathogenicity of MAP Strains
  12. Host Infectio
  13. MAP Antigens
  14. Alternative Tests of Cognitive Function
  15. Secret Operations: Intestinal Epithelial Cells, Macrophages and MAP
  16. Alternative Therapy
  17. GENOMIC AND RAPID RESPONSE PATHWAY TO VITAMIN D
  18. Enumeration of MAP
  19. Drug Susceptibility Testing for MAP, Why Bother?